IQUIX Drug Patent Profile
✉ Email this page to a colleague
When do Iquix patents expire, and when can generic versions of Iquix launch?
Iquix is a drug marketed by Santen and is included in one NDA.
The generic ingredient in IQUIX is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iquix
A generic version of IQUIX was approved as levofloxacin by RISING on December 20th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IQUIX?
- What are the global sales for IQUIX?
- What is Average Wholesale Price for IQUIX?
Summary for IQUIX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Patent Applications: | 5,337 |
DailyMed Link: | IQUIX at DailyMed |
US Patents and Regulatory Information for IQUIX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Santen | IQUIX | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021571-001 | Mar 1, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IQUIX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Santen | IQUIX | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021571-001 | Mar 1, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for IQUIX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Chiesi Farmaceutici S.p.A | Quinsair | levofloxacin | EMEA/H/C/002789 Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Authorised | no | no | no | 2015-03-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for IQUIX
See the table below for patents covering IQUIX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 8811867 | OPTICALLY ACTIVE DERIVATIVE OF BENZOXAZINE | ⤷ Sign Up |
Slovenia | 8912098 | PROCESS FOR OBTAINING A DERIVAT OF S(-) PYRIDOBENZ-OXAZIN | ⤷ Sign Up |
Yugoslavia | 209889 | ⤷ Sign Up | |
Germany | 19875012 | ⤷ Sign Up | |
Croatia | P950176 | OPTICALLY ACTIVE BENZOXAZINE DERIVATIVES | ⤷ Sign Up |
Australia | 585995 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IQUIX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0206283 | C980016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
0206283 | 98C0041 | Belgium | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
0206283 | SPC/GB97/085 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |